Superworth

Ionis Pharmaceuticals EV/EBIT IONS

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2015.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
224×
Feb 2023
9-year median
75.4×
9-year range
12.4× to 255×
Peer median
57.7×

Ionis Pharmaceuticals has no meaningful EV/EBIT today: it made an operating loss of $594.4M over the last twelve months.

It was last meaningful in Feb 2023, at 224×.

On the days it had one over the last 9 years, its median was 75.4×, from 12.4× in Mar 2020 to 255× in Nov 2022.

EV/EBIT over time

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2023224×224×239×
2022218×216×255×
202159.4×58.7×64.4×
202058.0×12.4×63.8×
201961.5×57.0×131×
2018167×70.1×203×
201775.8×66.7×241×
2016n/m a value too high to mean anything
2015249×185×249×

Against its peers

Companies in Drug Manufacturers - General nearest Ionis Pharmaceuticals' size, closest first, today.

CompanyEV/EBIT
IONSIonis Pharmaceuticalsn/m
ALKSAlkermes plc.69.6×
AMRXAmneal Pharmaceuticals18.3×
TGTXTG Therapeutics62.2×
LGNDLigand Pharmaceuticals57.7×
KNSAKiniksa Pharmaceuticals International54.6×
PTGXProtagonist Therapeutics140×
CORTCorcept Therapeuticsn/m
BMRNBiomarin Pharmaceutical25.8×
INDVIndivior Pharmaceuticals7.8×
ARQTArcutis Biotherapeutics111×
Peer median57.7×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Ionis Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.